Hi
I'm pleased to present a brief video update on whats happening at MindBio.
We recently reported a sustained anti-depressant response from microdosing MB220001 at 1 months and 3 months post cessation of an 8-week treatment cycle.
Our women's health trials in PMS and PMDD have also been approved to start dosing and Haywood Securities have recently signed on to provide strategic investment advisory to the company.
Join me to find out more about whats happening at MindBio.
We thank you for your support and interest in our scientific work.
Click on the link to view the video here
Stay Well!
JUSTIN HANKA
Chief Executive Officer & Co-Founder
MindBio Therapeutics Corp (Frankfurt: WF6), (CNSX: MBIO)
Follow CEO Justin Hanka on LinkedIn:
https://www.linkedin.com/in/justinhanka/
Follow MindBio on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true
0 comments